Look, you’ve all seen the news, so I probably don’t need to provide the details: Lilly won FDA approval for Zepbound in obesity. It’s the same ingredient in Mounjaro and
We’re into the heavy part of the drug-wonk season, so today’s newsletter packs in -- frankly -- a bit more than I would ordinarily like to throw at you (especially
Lots of earnings this morning that I haven’t processed yet. Hoping to give those a good look this weekend. Until then … The government formally responded to AstraZeneca’s lawsuit alleging